Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018.

Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Castillo J, Chandler JC, Costello C, Faiman M, Fung HC, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kang Y, Kassim A, Liedtke M, Malek E, Martin T, Neppalli VT, Omel J, Raje N, Singhal S, Somlo G, Stockerl-Goldstein K, Weber D, Yahalom J, Kumar R, Shead DA.

J Natl Compr Canc Netw. 2018 Jan;16(1):11-20. doi: 10.6004/jnccn.2018.0002.

PMID:
29295877
2.

Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States.

Muffly L, Pasquini MC, Martens M, Brazauskas R, Zhu X, Adekola K, Aljurf M, Ballen KK, Bajel A, Baron F, Battiwalla M, Beitinjaneh A, Cahn JY, Carabasi M, Chen YB, Chhabra S, Ciurea S, Copelan E, D'Souza A, Edwards J, Foran J, Freytes CO, Fung HC, Gale RP, Giralt S, Hashmi SK, Hildebrandt GC, Ho V, Jakubowski A, Lazarus H, Luskin MR, Martino R, Maziarz R, McCarthy P, Nishihori T, Olin R, Olsson RF, Pawarode A, Peres E, Rezvani AR, Rizzieri D, Savani BN, Schouten HC, Sabloff M, Seftel M, Seo S, Sorror ML, Szer J, Wirk BM, Wood WA, Artz A.

Blood. 2017 Aug 31;130(9):1156-1164. doi: 10.1182/blood-2017-03-772368. Epub 2017 Jul 3.

3.

Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.

Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Faiman M, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Liedtke M, Martin T, Omel J, Raje N, Reu FJ, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R.

J Natl Compr Canc Netw. 2017 Feb;15(2):230-269.

PMID:
28188192
4.

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.

Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Reu FJ, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R.

J Natl Compr Canc Netw. 2016 Apr;14(4):389-400.

5.

Donor Lymphocyte Infusion in Hematologic Malignancies--Good to be Fresh?

Hossain NM, Klumpp T, Ulicny J, Garner M, Kropf PL, Mangan KF, Barta SK, Fung HC, Martin ME.

Clin Lymphoma Myeloma Leuk. 2016 Feb;16(2):111-5. doi: 10.1016/j.clml.2015.10.004. Epub 2015 Nov 3.

PMID:
26632076
6.

Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.

Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Singhal S, Smith C, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2015 Nov;13(11):1398-435.

7.

The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen.

Urbano-Ispizua A, Pavletic SZ, Flowers ME, Klein JP, Zhang MJ, Carreras J, Montoto S, Perales MA, Aljurf MD, Akpek G, Bredeson CN, Costa LJ, Dandoy C, Freytes CO, Fung HC, Gale RP, Gibson J, Hamadani M, Hayashi RJ, Inamoto Y, Inwards DJ, Lazarus HM, Maloney DG, Martino R, Munker R, Nishihori T, Olsson RF, Rizzieri DA, Reshef R, Saad A, Savani BN, Schouten HC, Smith SM, Socié G, Wirk B, Yu LC, Saber W.

Biol Blood Marrow Transplant. 2015 Oct;21(10):1746-53. doi: 10.1016/j.bbmt.2015.05.010. Epub 2015 May 15.

8.

A phase 1 dose-escalation study of XmAb® 2513 in patients with relapsed or refractory Hodgkin lymphoma.

Kumar A, Blum KA, Fung HC, Smith MR, Foster PA, Younes A.

Br J Haematol. 2015 Mar;168(6):902-4. doi: 10.1111/bjh.13152. Epub 2014 Oct 1. No abstract available.

PMID:
25271537
9.

Gastrointestinal side effects and adequacy of enteral intake in hematopoietic stem cell transplant patients.

Walrath M, Bacon C, Foley S, Fung HC.

Nutr Clin Pract. 2015 Apr;30(2):305-10. doi: 10.1177/0884533614547084. Epub 2014 Sep 16.

10.

Anger, provider responses, and pain: prospective analysis of stem cell transplant patients.

Gerhart JI, Sanchez Varela V, Burns JW, Hobfoll SE, Fung HC.

Health Psychol. 2015 Mar;34(3):197-206. doi: 10.1037/hea0000095. Epub 2014 Aug 18.

PMID:
25133836
11.

Older patients with myeloma derive similar benefit from autologous transplantation.

Sharma M, Zhang MJ, Zhong X, Abidi MH, Akpek G, Bacher U, Callander NS, Dispenzieri A, Freytes CO, Fung HC, Gale RP, Gasparetto C, Gibson J, Holmberg LA, Kindwall-Keller TL, Klumpp TR, Krishnan AY, Landau HJ, Lazarus HM, Lonial S, Maiolino A, Marks DI, Mehta P, Mikhael Med JR, Nishihori T, Olsson R, Ramanathan M, Roy V, Savani BN, Schouten HC, Scott E, Tay J, To LB, Vesole DH, Vogl DT, Hari P.

Biol Blood Marrow Transplant. 2014 Nov;20(11):1796-803. doi: 10.1016/j.bbmt.2014.07.013. Epub 2014 Jul 18.

12.

Dosing algorithm for concomitant administration of sirolimus, tacrolimus, and an azole after allogeneic hematopoietic stem cell transplantation.

Peksa GD, Schultz K, Fung HC.

J Oncol Pharm Pract. 2015 Dec;21(6):409-15. doi: 10.1177/1078155214539825. Epub 2014 Jun 17.

13.

Sequential single-agent obatoclax mesylate (GX15-070MS) followed by combination with rituximab in patients with previously untreated follicular lymphoma.

Goy A, Berger M, Ford P, Feldman T, Mato A, Bejot C, Fung HC.

Leuk Lymphoma. 2014 Dec;55(12):2932-4. doi: 10.3109/10428194.2014.900760. Epub 2014 Apr 22. No abstract available.

PMID:
24611663
14.

Loss of CD26 protease activity in recipient mice during hematopoietic stem cell transplantation results in improved transplant efficiency.

Yoo E, Paganessi LA, Alikhan WA, Paganessi EA, Hughes F, Fung HC, Rich E, Seong CM, Christopherson KW 2nd.

Transfusion. 2013 Apr;53(4):878-87. doi: 10.1111/j.1537-2995.2012.03826.x. Epub 2012 Aug 6.

15.

CD26 protease inhibition improves functional response of unfractionated cord blood, bone marrow, and mobilized peripheral blood cells to CXCL12/SDF-1.

Christopherson KW 2nd, Frank RR, Jagan S, Paganessi LA, Gregory SA, Fung HC.

Exp Hematol. 2012 Nov;40(11):945-52. doi: 10.1016/j.exphem.2012.07.009. Epub 2012 Jul 27.

16.

A simplified technique for delivering total body irradiation (TBI) with improved dose homogeneity.

Yao R, Bernard D, Turian J, Abrams RA, Sensakovic W, Fung HC, Chu JC.

Med Phys. 2012 Apr;39(4):2239-48. doi: 10.1118/1.3697526.

PMID:
22482645
17.

Cellular therapies supplement: strategies for improving transplant efficiency in the context of cellular therapeutics.

Jimenez A, Fung HC, Christopherson KW 2nd.

Transfusion. 2011 Nov;51 Suppl 4:125S-137S. doi: 10.1111/j.1537-2995.2011.03375.x.

PMID:
22074623
18.

Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma.

Karmali R, Kassar M, Venugopal P, Shammo JM, Fung HC, Bayer R, O'Brien T, Gregory SA.

Clin Lymphoma Myeloma Leuk. 2011 Dec;11(6):467-74. doi: 10.1016/j.clml.2011.04.009. Epub 2011 Jun 22.

PMID:
21700527
19.

In vivo expansion of the megakaryocyte progenitor cell population in adult CD26-deficient mice.

Kidd S, Bueso-Ramos C, Jagan S, Paganessi LA, Boggio LN, Fung HC, Gregory SA, Christopherson KW 2nd.

Exp Hematol. 2011 May;39(5):580-590.e1. doi: 10.1016/j.exphem.2011.01.012. Epub 2011 Feb 1.

PMID:
21291952
20.

Effective mobilization of hematopoietic progenitor cells in G-CSF mobilization defective CD26-/- mice through AMD3100-induced disruption of the CXCL12-CXCR4 axis.

Paganessi LA, Walker AL, Tan LL, Holmes I, Rich E, Fung HC, Christopherson KW 2nd.

Exp Hematol. 2011 Mar;39(3):384-90. doi: 10.1016/j.exphem.2010.12.003. Epub 2010 Dec 17.

21.

Induction chemotherapy before autologous stem cell transplantation for symptomatic plasma cell myeloma - does it matter?

Fung HC, Nathan S, Maciejewski JJ.

Clin Pharmacol. 2010;2:71-5. doi: 10.2147/CPAA.S6258. Epub 2010 Apr 14.

22.

Mesenchymal stem cells from the Wharton's jelly of umbilical cord segments provide stromal support for the maintenance of cord blood hematopoietic stem cells during long-term ex vivo culture.

Bakhshi T, Zabriskie RC, Bodie S, Kidd S, Ramin S, Paganessi LA, Gregory SA, Fung HC, Christopherson KW 2nd.

Transfusion. 2008 Dec;48(12):2638-44. doi: 10.1111/j.1537-2995.2008.01926.x. Epub 2008 Sep 16.

23.

Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma.

Krishnan A, Nademanee A, Fung HC, Raubitschek AA, Molina A, Yamauchi D, Rodriguez R, Spielberger RT, Falk P, Palmer JM, Forman SJ.

J Clin Oncol. 2008 Jan 1;26(1):90-5. Epub 2007 Nov 19.

PMID:
18025438
24.

Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma.

Fung HC, Stiff P, Schriber J, Toor A, Smith E, Rodriguez T, Krishnan A, Molina A, Smith D, Ivers B, Kogut N, Popplewell L, Rodriguez R, Somlo G, Forman SJ, Nademanee A.

Biol Blood Marrow Transplant. 2007 May;13(5):594-600. Epub 2007 Mar 23.

25.

Interleukin-2 after autologous stem-cell transplantation for adult patients with acute myeloid leukemia in first complete remission.

Stein AS, O'Donnell MR, Slovak ML, Snyder DS, Nademanee AP, Parker P, Molina A, Somlo G, Fung HC, Krishnan A, Rodriguez R, Spielberger RT, Wang S, Dagis A, Vora N, Arber DA, Niland JC, Forman SJ.

J Clin Oncol. 2003 Feb 15;21(4):615-23.

PMID:
12586797
26.

Approach to Hodgkin's lymphoma in the new millennium.

Fung HC, Nademanee AP.

Hematol Oncol. 2002 Mar;20(1):1-15. Review.

PMID:
11921013

Supplemental Content

Loading ...
Support Center